نتائج البحث - "Nixon MJ"

المساهمون: Formisano, L, Lu, Y, Servetto, A, Hanker, Ab, Jansen, Vm, Bauer, Ja, Sudhan, Dr, Guerrero-Zotano, Al, Croessmann, S, Guo, Y, Ericsson, Pg, Lee, Km, Nixon, Mj, Schwarz, Lj, Sanders, Me, Dugger, Tc, Cruz, Mr, Behdad, A, Cristofanilli, M, Bardia, A, O'Shaughnessy, J, Nagy, Rj, Lanman, Rb, Solovieff, N, He, W, Miller, M, Su, F, Shyr, Y, Mayer, Ia, Balko, Jm, Arteaga, Cl.

المصدر: Nature Communications, Vol 10, Iss 1, Pp 1-14 (2019)
Nature Communications

مصطلحات موضوعية: 0301 basic medicine, Pyridines, General Physics and Astronomy, Aminopyridines, 02 engineering and technology, Drug resistance, Tyrosine-kinase inhibitor, Piperazines, Circulating Tumor DNA, chemistry.chemical_compound, Mice, Erdafitinib, Antineoplastic Combined Chemotherapy Protocols, Cyclin D1, lcsh:Science, Abemaciclib, Fulvestrant, cancer cell, Multidisciplinary, drug, High-Throughput Nucleotide Sequencing, 021001 nanoscience & nanotechnology, Progression-Free Survival, 3. Good health, inhibitor, Receptors, Estrogen, MCF-7 Cells, Quinolines, Female, biological phenomena, cell phenomena, and immunity, 0210 nano-technology, medicine.drug, Signal Transduction, identification method, Antineoplastic Agents, Hormonal, medicine.drug_class, Science, Breast Neoplasms, Palbociclib, Naphthalenes, General Biochemistry, Genetics and Molecular Biology, Article, resistance, 03 medical and health sciences, Breast cancer, Quinoxalines, medicine, Animals, Humans, Progression-free survival, Receptor, Fibroblast Growth Factor, Type 1, Receptor, Fibroblast Growth Factor, Type 2, Protein Kinase Inhibitors, Proportional Hazards Models, business.industry, Cyclin-Dependent Kinase 4, General Chemistry, DNA, Cyclin-Dependent Kinase 6, medicine.disease, Xenograft Model Antitumor Assays, stomatognathic diseases, 030104 developmental biology, chemistry, Drug Resistance, Neoplasm, Purines, Mutation, Cancer research, Pyrazoles, lcsh:Q, survival tumor, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::867afa6a277eebe06a4fa212f3467c8a
https://doaj.org/article/c9a8bb9c2aac44dba476758c76c4a8d4

Find this article in full text from ProQuest

7

Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial

المؤلفون: Mellissa J. Nixon, Sarah Croessmann, Justin M. Balko, Carlos L. Arteaga, Paula Gonzalez Ericsson, Alshad S. Lalani, Melinda E. Sanders, Dhivya R. Sudhan, Francesca Avogadri-Connors, Angel Guerrero-Zotano, Alan Auerbach, Richard Bryce, Luigi Formisano, Luis J. Schwarz, Richard E. Cutler

المساهمون: Sudhan, Dr, Schwarz, Lj, Guerrero-Zotano, A, Formisano, L, Nixon, Mj, Croessmann, S, González Ericsson, Pi, Sanders, M, Balko, Jm1, Avogadri-Connors, F, Cutler, Re, Lalani, A, Bryce, R, Auerbach, A, Arteaga, Cl.

المصدر: Clinical Cancer Research. 25:771-783

مصطلحات موضوعية: 0301 basic medicine, Cancer Research, Receptor, ErbB-2, Breast Neoplasms, Article, Mice, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Cyclin D1, Trastuzumab, ErbB, Cell Line, Tumor, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, medicine, Adjuvant therapy, Animals, Humans, skin and connective tissue diseases, Fulvestrant, business.industry, Immunohistochemistry, Xenograft Model Antitumor Assays, Disease Models, Animal, Treatment Outcome, 030104 developmental biology, Receptors, Estrogen, Oncology, Paclitaxel, chemistry, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Neratinib, Quinolines, Cancer research, Female, Pertuzumab, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10ad751a195f1e7d9b46df2856ca2461
https://doi.org/10.1158/1078-0432.ccr-18-1131

8

دورية أكاديمية

Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancer.

المؤلفون: Hanna A; Departments of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, 2200 Pierce Ave, 777 PRB, Nashville, TN, 37232, USA., Nixon MJ; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.; Department of Early Discovery Oncology, Merck & Co., Boston, MA, USA., Estrada MV; Department of Pathology, Microbiology & Immunology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, 2200 Pierce Ave, 777 PRB, Nashville, TN, 37232, USA.; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, 2200 Pierce Ave, 777 PRB, Nashville, TN, 37232, USA., Sanchez V; Department of Pathology, Microbiology & Immunology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, 2200 Pierce Ave, 777 PRB, Nashville, TN, 37232, USA., Sheng Q; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA., Opalenik SR; Departments of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, 2200 Pierce Ave, 777 PRB, Nashville, TN, 37232, USA., Toren AL; Departments of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, 2200 Pierce Ave, 777 PRB, Nashville, TN, 37232, USA., Bauer J; Vanderbilt Institute of Chemical Biology, Nashville, TN, USA., Owens P; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Mason FM; Departments of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, 2200 Pierce Ave, 777 PRB, Nashville, TN, 37232, USA., Cook RS; Biomedical Engineering, Vanderbilt University School of Engineering, Nashville, TN, USA., Sanders ME; Department of Pathology, Microbiology & Immunology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, 2200 Pierce Ave, 777 PRB, Nashville, TN, 37232, USA.; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, 2200 Pierce Ave, 777 PRB, Nashville, TN, 37232, USA., Arteaga CL; Simmons Comprehensive Cancer Center, University of Texas Southwester, Dallas, TX, USA., Balko JM; Departments of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, 2200 Pierce Ave, 777 PRB, Nashville, TN, 37232, USA. justin.balko@vumc.org.; Department of Pathology, Microbiology & Immunology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, 2200 Pierce Ave, 777 PRB, Nashville, TN, 37232, USA. justin.balko@vumc.org.; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, 2200 Pierce Ave, 777 PRB, Nashville, TN, 37232, USA. justin.balko@vumc.org.

المصدر: Breast cancer research : BCR [Breast Cancer Res] 2022 Jul 18; Vol. 24 (1), pp. 51. Date of Electronic Publication: 2022 Jul 18.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.

بيانات الدورية: Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 100927353 Publication Model: Electronic Cited Medium: Internet ISSN: 1465-542X (Electronic) Linking ISSN: 14655411 NLM ISO Abbreviation: Breast Cancer Res Subsets: MEDLINE

Find this article in full text from Springer Verlag.

Find this article in full text from ProQuest

Full Text Finder

9

تقرير

Subacute fat embolism syndrome in a young female trauma patient during COVID-19.

المؤلفون: Nixon MJ; Medical Sciences Division, University of Oxford, Oxford, UK., Grant T; ST4 Anaesthetics, Oxford School of Anaesthesia, Oxford, UK.

المصدر: Journal of surgical case reports [J Surg Case Rep] 2021 Oct 26; Vol. 2021 (10), pp. rjab485. Date of Electronic Publication: 2021 Oct 26 (Print Publication: 2021).

نوع المنشور: Case Reports

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 101560169 Publication Model: eCollection Cited Medium: Print ISSN: 2042-8812 (Print) Linking ISSN: 20428812 NLM ISO Abbreviation: J Surg Case Rep Subsets: PubMed not MEDLINE

Full Text Finder

10

دورية أكاديمية

Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer.

المؤلفون: Axelrod ML; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Nixon MJ; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Gonzalez-Ericsson PI; Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville, Tennessee., Bergman RE; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Pilkinton MA; Department of Infectious Disease, Vanderbilt University Medical Center, Nashville, Tennessee., McDonnell WJ; Department of Infectious Disease, Vanderbilt University Medical Center, Nashville, Tennessee., Sanchez V; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.; Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville, Tennessee., Opalenik SR; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Loi S; Department of Oncology, University of Melbourne and Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Zhou J; IsoPlexis Corporation, Branford, Connecticut., Mackay S; IsoPlexis Corporation, Branford, Connecticut., Rexer BN; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Abramson VG; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Jansen VM; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Mallal S; Department of Infectious Disease, Vanderbilt University Medical Center, Nashville, Tennessee., Donaldson J; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Krop IE; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Garrido-Castro AC; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Marotti JD; Department of Pathology & Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.; Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire., Shee K; Department of Molecular & Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire., Miller TW; Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.; Department of Molecular & Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire., Sanders ME; Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville, Tennessee.; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee., Mayer IA; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.; Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville, Tennessee., Salgado R; Department of Oncology, University of Melbourne and Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium., Balko JM; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. justin.balko@vumc.org.; Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville, Tennessee.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Nov 01; Vol. 26 (21), pp. 5668-5681. Date of Electronic Publication: 2020 Aug 21.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Albumins/*administration & dosage , B7-H1 Antigen/*genetics , Paclitaxel/*administration & dosage , Programmed Cell Death 1 Receptor/*genetics , Triple Negative Breast Neoplasms/*drug therapy, Adult ; Aged ; Albumins/adverse effects ; Antineoplastic Combined Chemotherapy Protocols ; B7-H1 Antigen/antagonists & inhibitors ; CD8-Positive T-Lymphocytes/drug effects ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Lymphocytes, Tumor-Infiltrating/drug effects ; Lymphocytes, Tumor-Infiltrating/immunology ; Middle Aged ; Neoadjuvant Therapy/adverse effects ; Neoplasm Proteins/genetics ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/immunology ; Neoplasm Recurrence, Local/pathology ; Paclitaxel/adverse effects ; Prognosis ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Progression-Free Survival ; Treatment Outcome ; Triple Negative Breast Neoplasms/genetics ; Triple Negative Breast Neoplasms/immunology ; Triple Negative Breast Neoplasms/pathology ; Tumor Microenvironment/drug effects

تنقيح النتائج